VIPoma of the Pancreas
Praxis (Bern 1994). 2021 Sep;110(11):637-642. doi: 10.1024/1661-8157/a003714.ABSTRACTVIPoma of the Pancreas Abstract. A 50-year old man was admitted for evaluation of progressive, chronic diarrhea with loss of weight and recurrent hypokalemia. Eventually, a neuroendocrine tumor of the pancreas secreting VIP (VIPoma) could be diagnosed. The patient was cured by a pancreaticoduodenectomy (Whipple procedure). With this case, we want to highlight the importance of a structured work-up in chronic diarrhea including thorough history and clinical assessment, laboratory tests and imaging studies.PMID:34465193 | DOI:10.1024/1661-81...
Source: Praxis - September 1, 2021 Category: General Medicine Authors: Andreas Steck Christian Nebiker Jo ël Capraro H üseyin Yurtsever Ali Al Toutonji Tristan Struja Source Type: research
Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d ’étude des Tumeurs Endocrines) Study
ConclusionIn MEN1 patients, pancreatoduodenectomy can be used to control hormone secretions (gastrin, glucagon, VIP) and to remove large NETs. PD was found to control gastrin secretions in about 60% of cases. (Source: World Journal of Surgery)
Source: World Journal of Surgery - May 4, 2021 Category: Surgery Source Type: research
Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study
ConclusionThe octreotide pen injector and IFU were usable by self-trained participants. Participant errors and suggestions provided a foundation for recommendations to improve the IFU. (Source: Advances in Therapy)
Source: Advances in Therapy - May 4, 2021 Category: Drugs & Pharmacology Source Type: research
A Case of Metastatic VIPoma With Complete Response to Peptide Radionuclide Receptor Therapy
No abstract available (Source: Pancreas)
Source: Pancreas - April 1, 2021 Category: Gastroenterology Tags: Letters to the Editor Source Type: research
Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.
Authors: Lam AK, Ishida H
Abstract
The nomenclature and classification of pancreatic neuroendocrine neoplasms has evolved in the last 15 years based on the advances in knowledge of the genomics, clinical behaviour and response to therapies. The current 2019 World Health Organization classification of pancreatic neuroendocrine neoplasms categorises them into three groups; pancreatic neuroendocrine tumours (PanNETs)(grade 1 grade 2, grade 3), pancreatic neuroendocrine carcinomas and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) based on the mitotic rate, Ki-67 index, morphological differentiatio...
Source: Histology and Histopathology - December 13, 2020 Category: Cytology Tags: Histol Histopathol Source Type: research
Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients.
Conclusion: Patients with suspected functional PanNENs should have a systematic endocrine examination at diagnosis. Multidisciplinary collaborations are essential for precise diagnosis and tumor localization. A successful surgery or other targeted therapies can improve the prognosis of patients with such rare but complex disorders.
PMID: 33204258 [PubMed] (Source: International Journal of Endocrinology)
Source: International Journal of Endocrinology - November 20, 2020 Category: Endocrinology Tags: Int J Endocrinol Source Type: research
Percutaneous Cryoablation of Recurrent Pancreatic Mass for Life-Threatening Pancreatic VIPoma Syndrome: A Case Report
We present the case of a 73-year-old female who underwent percutaneous cryoablation for recurrent life-threatening pancreatic vasoactive intestinal polypeptide-producing tumor (VIPoma) following a pancreaticoduodenectomy and chemotherapy 5 years earlier. She presented with profuse watery diarrhea causing severe electrolyte and acid–base abnormalities, along with acute kidney injury. Cryoablation was successful in treating her profound symptoms, completely reversing her clinical course. The patient has made a successful recovery fo r the last 1.5 years since the procedure. (Source: CardioVascular and Interventional Radiology)
Source: CardioVascular and Interventional Radiology - September 9, 2020 Category: Radiology Source Type: research
Vasoactive intestinal peptide-oma causing refractory diarrhea in a young woman.
We describe a 36-year-old woman presenting with a 2-year history of severe diarrhea and electrolyte derangements ultimately diagnosed with VIPoma.
PMID: 33100555 [PubMed] (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - July 7, 2020 Category: Universities & Medical Training Authors: Shankar N, Linzay C, Rowe K Tags: Proc (Bayl Univ Med Cent) Source Type: research
Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide
No abstract available (Source: Pancreas)
Source: Pancreas - March 1, 2020 Category: Gastroenterology Tags: Letters to the Editor Source Type: research
Vasoactive Intestinal Peptide–Secreting Tumors: A Review
Vasoactive intestinal peptide–secreting tumors (VIPomas) are a group of rare neuroendocrine tumors, which cause a typical syndrome of watery diarrhea. Most of these tumors are found in the pancreas and are usually detected at a later stage. Although curative resection is not possible in most of these tumors, both symptom and tumor control can be achieved by a multidimensional approach, to enable a long survival of most patients. There are no clear-cut guidelines for the management of VIPomas because of the rarity of this neoplasm and lack of prospective data. In this review, we discuss the available evidence on the clini...
Source: Pancreas - October 1, 2019 Category: Gastroenterology Tags: Reviews Source Type: research
Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors: A Series of 15 Patients
Conclusions
The management of VIPomas is challenging requiring the application of multiple treatment modalities. Patients who underwent surgical treatment with curative intent appear to have higher survival rate. Central registration and larger prospective studies are required to evaluate the effect of currently employed therapies in these patients. (Source: Pancreas)
Source: Pancreas - July 16, 2019 Category: Gastroenterology Tags: Original Articles Source Type: research
Life-threating diarrhea and acute renal failure secondary to pancreatic VIPoma treated by surgery: a clinical case.
We present the case of a 46-year-old patient who developed a prerenal kidney failure secondary to severe watery diarrhea after a diagnosis of pancreatic VIPoma. Thus, a resection was performed as the patient was rapidly deteriorating and required an intervention.
PMID: 31232078 [PubMed - as supplied by publisher] (Source: Revista Espanola de Enfermedades Digestivas)
Source: Revista Espanola de Enfermedades Digestivas - June 26, 2019 Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.
CONCLUSIONS: VIPomas are functional tumors that secrete excessive amounts of VIP. Clinically, production of VIP causes refractory watery diarrhea, hypokalemia and achlorydria. As far as diagnosis is concerned, elevated VIP plasma levels are required. Moreover, the majority of VIPomas are malignant or have already metastasized on diagnosis. Despite recent research on the therapeutic strategies against pancreatic VIPoma, surgical resection appears as the only potentially curative approach.
PMID: 31127985 [PubMed - in process] (Source: Journal of B.U.ON.)
Source: Journal of B.U.ON. - May 29, 2019 Category: Cancer & Oncology Tags: J BUON Source Type: research
Chronic Diarrhea Secondary to Newly Diagnosed VIPoma
We present a case of a male with 6 months of diarrhea and malaise who was found to have significant kidney injury and hypokalemia requiring admission to the medical intensive care unit. Subsequent laboratory evaluation while admitted eventually showed a low stool osmotic gap ( –11 mOsm/kg) consistent with secretory diarrhea, in addition to significantly elevated VIP levels at 940 pg/mL (normal #x3c;75). Cross-sectional imaging with functional Gallium-68 dotatate PET-CT confirmed metastatic functional neuroendocrine tumor indicative of a VIPoma. Pathology on subsequent m etastatic liver lesion aspiration was consistent wi...
Source: Case Reports in Gastroenterology - April 24, 2019 Category: Gastroenterology Source Type: research
Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors.
Conclusion: Treatment with 177Lu-DOTATATE is a safe and effective therapy resulting in radiological, symptomatic and biochemical response in a high percentage of patients with metastatic functioning pNETs. Hormonal crises occur relatively frequent and preventive therapy should be considered before and/or during PRRT.
PMID: 30566620 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - December 18, 2018 Category: Endocrinology Authors: Zandee WT, Brabander T, Blaževic A, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, de Herder WW Tags: J Clin Endocrinol Metab Source Type: research
